Fox Run Management L.L.C. Has $976,000 Holdings in Biogen Inc. $BIIB

Fox Run Management L.L.C. decreased its holdings in Biogen Inc. (NASDAQ:BIIB) by 45.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 6,969 shares of the biotechnology company’s stock after selling 5,922 shares during the quarter. Fox Run Management L.L.C.’s holdings in Biogen were worth $976,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in BIIB. Elevation Point Wealth Partners LLC bought a new stake in Biogen in the 2nd quarter valued at $25,000. Rothschild Investment LLC increased its holdings in shares of Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the last quarter. NewSquare Capital LLC raised its position in shares of Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares during the period. WFA of San Diego LLC bought a new position in shares of Biogen in the second quarter valued at about $32,000. Finally, True Wealth Design LLC lifted its stake in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Tudor Pickering set a $201.00 price target on shares of Biogen in a research note on Monday, February 9th. TD Cowen boosted their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Citigroup upped their target price on Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. UBS Group assumed coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target for the company. Finally, BMO Capital Markets boosted their price target on Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research note on Friday, February 6th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, Biogen presently has an average rating of “Hold” and a consensus price target of $205.04.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $188.02 on Friday. The stock has a market capitalization of $27.59 billion, a PE ratio of 21.34, a P/E/G ratio of 1.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The business has a fifty day moving average price of $181.64 and a two-hundred day moving average price of $162.83. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the firm earned $3.44 earnings per share. Biogen’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.